

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



RemeGen Co., Ltd.*

榮昌生物製藥(煙台)股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 9995)

2026 THIRD QUARTERLY REPORT

This announcement is made pursuant to Rules 13.09(2)(a) and 13.10B of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited and the Inside Information Provisions under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

Reference is made to the “RemeGen Co., Ltd.* 2026 Third Quarterly Report”(the “**2026 Third Quarterly Report**”) published by RemeGen Co., Ltd.* (the “**Company**”) on the website of the Shanghai Stock Exchange, for reference purpose only. The following is a translation of the 2026 Third Quarterly Report solely for the purpose of providing information. Should there be any discrepancies, the Chinese version shall prevail.

The board of directors of the Company (the “**Board**”) reminds shareholders and potential investors of the Company that the information and financial data set out in this announcement are unaudited, have been reviewed by the audit committee of the Company, but have not been reviewed by the independent auditors of the Company.

The unaudited financial data in the 2026 Third Quarterly Report set out in this announcement is prepared in accordance with the accounting principles of the People's Republic of China instead of the International Financial Reporting Standards, and is prepared pursuant to the requirements of the STAR Market of the Shanghai Stock Exchange only.

Shareholders and potential investors are advised to exercise caution when dealing in securities of the Company.

By order of the Board
RemeGen Co., Ltd.*
Mr. Wang Weidong
Chairman and executive director

Yantai, PRC
October 29, 2026

As at the date of this announcement, the Board comprises Mr. Wang Weidong, Dr. Fang Jianmin, Mr. Wen Qingkai, Ms. Fang Michelle Yi and Mr. Wang Yuxiao as the executive directors, Dr. Wang Liqiang as the non-executive director, and Mr. Song Xiliang, Mr. Huang Guobin and Mr. Chen Yunjin as the independent non-executive directors.

* For identification purpose only

Stock Code: 688331

Ticker Symbol: RemeGen

RemeGen Co., Ltd.*

2026 THIRD QUARTERLY REPORT

The board of directors and all directors of the Company undertake that there are no false representations or misleading statements contained in, or material omissions from, this announcement, and accept responsibilities for the truthfulness, accuracy and completeness of its contents in accordance with the applicable laws.

IMPORTANT NOTICE:

The board of directors, directors, and senior management of the Company undertake that the content of the quarterly report is true, accurate, complete and without any false representations, misleading statements or material omissions and are severally and jointly liable therefor.

The Company's legal representative, person in charge of accounting function and person in charge of the accounting department (chief accounting officer) warrant the truthfulness, accuracy and completeness of the financial statements contained in the quarterly report.

Whether the third quarterly financial statements have been audited

☐ Yes ☒ No

I. KEY FINANCIAL INFORMATION

(i) Key accounting data and financial indicators

Unit: RMB Currency: Renminbi

Item	The Reporting Period	Increase/decrease of the Reporting Period compared with the same period of the previous year (%)	From the beginning of the year to the end of the Reporting Period	Increase/decrease from the beginning of the year to the end of the Reporting Period compared with the same period of the
------	----------------------	--	---	--

				previous year (%)
Operating revenue	910,487,645.29	46.41	6,763,781,382.06	293.28
Total profits	610,947,945.77	N/A	5,273,822,599.78	N/A
Net profit attributable to shareholders of the listed company	610,947,758.22	N/A	5,273,231,114.53	N/A
Net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses	73,691,712.94	N/A	4,412,043,059.88	N/A
Net cash flows from operating activities	N/A	N/A	4,083,694,402.44	1,781.39
Basic earnings per share (RMB/share)	1.09	N/A	9.41	N/A
Diluted earnings per share (RMB/share)	1.08	N/A	9.37	N/A
Weighted average return on equity (%)	5.75	An increase of 8.79 percentage points	84.13	An increase of 110.83 percentage points
Total R&D spending	281,124,273.61	15.51	695,272,999.40	-21.93
R&D spending as a percentage of operating revenue (%)	30.88	A decrease of 8.26 percentage points	10.28	A decrease of 41.5 percentage points
	As at the end of the Reporting Period	As at the end of the previous year		Increase/decrease at the end of the Reporting Period compared with the end of the previous year (%)
Total assets	10,546,341,735.44	7,248,072,288.97		45.51
Owners' equity attributable to shareholders of the listed company	8,892,746,778.63	3,608,821,657.57		146.42

Note: "The Reporting Period" means the three-month period from the beginning of the quarter to the end of the quarter, the same hereinafter.

(ii) Non-recurring items and amounts

√ Applicable □ Not Applicable

Unit: RMB Currency: Renminbi

Non-recurring items	Current amount	Amount for the period from the beginning of the year to the end of the Reporting Period	Description
Gains or losses on disposal of non-current assets, including the write-off of the asset impairment provisions	1,357.68	-1,391,650.21	Net losses on disposal of non-current assets
Government grants recognised as current profits and losses, except those that are closely related to the Company's ordinary course of business operations, comply with national policies, granted based on determined standards, and have a lasting impact on the Company's profits and losses	1,691,707.46	7,722,728.18	Government grants recognised as other income
Gains and losses from changes in fair value arising from financial assets and financial liabilities held by non-financial enterprises and profits and losses from disposal of financial assets and financial liabilities other than effective hedging business related to the Company's ordinary course of business operations	542,122,300.88	867,067,286.62	Profits from financial assets and gains and losses from changes in fair value
Other non-operating income and expenses other than the above items	-6,559,320.74	-12,210,309.94	Donation expenses in majority
Total	537,256,045.28	861,188,054.65	

Explanations are required for defining items that are not set out in the Explanatory Announcement No. 1 on Information Disclosure for Companies Offering Their Securities to the Public - Non-recurring Gains and Losses as non-recurring items with significant amounts and for defining the non-recurring items that are set out in the Explanatory Announcement No. 1 on Information Disclosure for Companies Offering Their Securities to the Public - Non-recurring Gains and Losses as recurring items.

√ Applicable ☐ Not Applicable

Unit: RMB Currency: Renminbi

Item	Amount involved	Reason
Additional value-added tax deductions	963,826.97	Tax incentives for business activities
Government grants related to long-term assets	6,201,598.73	Lasting impact on the Company's gains and losses
Refund of handling charge for personal tax	1,172,908.92	Tax incentives for operating

		activities
--	--	------------

(iii) Changes in key accounting data and financial indicators and reasons for changes

√ Applicable □ Not Applicable

Item	Percentage change (%)	Primary reason
Operating revenue_The Reporting Period	46.41	Primarily due to an increase in sales revenue as a result of the rise in sales volumes of telitacicept and disitamab vedotin for injection.
Operating revenue_From the beginning of the year to the end of the Reporting Period	293.28	Primarily due to an increase in sales revenue as a result of the rise in sales volumes of telitacicept and disitamab vedotin for injection and a substantial increase in technology licensing revenue resulting from the execution of an exclusive license agreement with AbbVie for RC148.
Total profit_The Reporting Period	N/A	Primarily due to the continued increase in revenue from sales of commercialised products and the changes in the fair value of warrants.
Total profit_From the beginning of the year to the end of the Reporting Period	N/A	1. Continued increase in revenue from sales of commercialized products; 2. A substantial increase in technology licensing revenue resulting from the execution of an exclusive license agreement with AbbVie for RC148; 3. Reduction in R&D spending due to technology licensing of products; 4. Changes in the fair value of warrants.
Net profit attributable to shareholders of the listed company_The Reporting Period	N/A	Primarily due to the continued increase in revenue from sales of commercialised products and the changes in the fair value of warrants.
Net profit attributable to shareholders of the listed company_From the beginning of the year to the end of the Reporting Period	N/A	1. Continued increase in revenue from sales of commercialized products; 2. A substantial increase in technology licensing revenue resulting from the execution of an exclusive license agreement with AbbVie for RC148; 3. Reduction in R&D spending due to technology licensing of products; 4. Changes in the fair value of warrants.
Net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses_The Reporting Period	N/A	Primarily due to an increase in sales revenue as a result of the rise in sales volumes of telitacicept and disitamab vedotin for injection.

Net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses_ From the beginning of the year to the end of the Reporting Period	N/A	Primarily due to a substantial increase in revenue from product sales and technology licensing and a reduction in R&D spending due to technology licensing of products.
Net cash flows from operating activities_ From the beginning of the year to the end of the Reporting Period	1,781.39	Primarily due to new cash inflows from significant-amount technology licensing during the year, together with higher product sales volumes, which results in increases in cash received from the sale of goods and provision of services and the net cash flow from operating activities.
Basic earnings per share (RMB/share)_The Reporting Period	N/A	Primarily due to a turnaround from loss to profit year-on-year caused by the aforementioned reasons
Basic earnings per share (RMB/share)_From the beginning of the year to the end of the Reporting Period	N/A	
Diluted earnings per share (RMB/share)_The Reporting Period	N/A	
Diluted earnings per share (RMB/share)_From the beginning of the year to the end of the Reporting Period	N/A	
Weighted average return on equity (%)_The Reporting Period	An increase of 8.79 percentage points	
Weighted average return on equity (%)_From the beginning of the year to the end of the Reporting Period	An increase of 110.83 percentage points	
R&D spending as a percentage of operating revenue (%)_From the beginning of the year to the end of the Reporting Period	A decrease of 41.5 percentage points	Primarily due to a significant increase in operating revenue caused by the aforementioned reasons
Total assets_ As at the end of the Reporting Period	45.51	Primarily due to new technology licensing.
Owners' equity attributable to shareholders of the listed	146.42	Primarily due to new technology licensing.

company_As at the end of the Reporting Period		
---	--	--

II. SHAREHOLDER INFORMATION

(i) Total number of ordinary shareholders, number of preferred shareholders with restored voting rights, and shareholding of the top ten shareholders

Unit: share

Total number of ordinary shareholders as at the end of the Reporting Period	27,501			Total number of preferred shareholders with restored voting rights as at the end of the Reporting Period (if any)			
Shareholding of the top ten shareholders (excluding shares re-lent)							
Name of shareholder	Nature of shareholder	Number of shares held	Shareholding ratio (%)	Number of restricted shares held	Number of restricted shares including shares re-lent	Shares pledged, marked and frozen	
						Share status	Quantity
HKSCC NOMINEES LIMITED	Unknown	208,550,213	36.95	0	0	Unknown	-
Yantai Rongda Venture Capital Center (Limited Partnership)	Domestic non-state-owned legal person	102,381,891	18.14	0	0	Nil	0
FANG JIANMIN	Overseas natural person	26,218,320	4.64	0	0	Nil	0
Yantai Rongqian Enterprise Management Center (Limited Partnership)	Domestic non-state-owned legal person	18,507,388	3.28	0	0	Nil	0

Yantai Rongyi Enterprise Management Center (Limited Partnership)	Domestic non-state-owned legal person	16,630,337	2.95	0	0	Nil	0
I-Nova Limited	Overseas legal person	13,600,000	2.41	0	0	Nil	0
Yantai Rongshi Enterprise Management Center (Limited Partnership)	Domestic non-state-owned legal person	9,190,203	1.63	0	0	Nil	0
HKSCC LIMITED	Overseas legal person	7,548,083	1.34	0	0	Nil	0
RongChang Holding Group LTD.	Overseas legal person	4,111,338	0.73	0	0	Nil	0
Industrial Bank Co., Ltd. - Maxwealth Pharmaceutical Innovation Smart Selection Hybrid Initiated Securities Investment Fund	Other	3,708,905	0.66	0	0	Nil	0
Shareholding of the top ten holders of unrestricted shares (excluding shares re-lent)							
Name of shareholder	Number of unrestricted outstanding shares held	Share type and quantity					
		Share type	Quantity				
HKSCC NOMINEES LIMITED	208,550,213	Overseas listed foreign shares	208,550,213				
Yantai Rongda Venture Capital Center (Limited Partnership)	102,381,891	RMB-denominated ordinary shares	102,381,891				
FANG JIANMIN	26,218,320	RMB-denominated ordinary shares	26,218,320				
Yantai Rongqian Enterprise Management Center (Limited Partnership)	18,507,388	RMB-denominated ordinary shares	18,507,388				

Yantai Rongyi Enterprise Management Center (Limited Partnership)	16,630,337	RMB-denominated ordinary shares	16,630,337
I-Nova Limited	13,600,000	RMB-denominated ordinary shares	13,600,000
Yantai Rongshi Enterprise Management Center (Limited Partnership)	9,190,203	RMB-denominated ordinary shares	9,190,203
HKSCC LIMITED	7,548,083	RMB-denominated ordinary shares	7,548,083
RongChang Holding Group LTD.	4,111,338	RMB-denominated ordinary shares	4,111,338
Industrial Bank Co., Ltd. - Maxwealth Pharmaceutical Innovation Smart Selection Hybrid Initiated Securities Investment Fund	3,708,905	RMB-denominated ordinary shares	3,708,905
Description of the connected relationship or concerted actions among the above shareholders	Yantai Rongda Venture Capital Center (Limited Partnership), FANG JIANMIN, I-Nova Limited and RongChang Holding Group LTD. established a concerted action relationship.		
Description of top ten shareholders and top ten holders of unrestricted shares in margin trading and re-lending business (if any)	Nil		

Note 1: As of the end of the Reporting Period, there were a total number of 27,481 Class A ordinary shareholders and 20 Class H ordinary shareholders, totalling 27,501 ordinary shareholders.

Note 2: The shares held by HKSCC NOMINEES LIMITED (香港中央結算(代理人)有限公司) are shares it holds on behalf of several clients, and part of the H shares held by FANG JIANMIN, I-Nova Limited and RongChang Holding Group LTD. are registered under HKSCC NOMINEES LIMITED.

Note 3: As of the end of the Reporting Period, the Company's special securities account for share repurchases held 254,184 shares, which accounted for 0.045% of the Company's total share capital and were not listed in the above "Shareholding of the top ten shareholders" and "Shareholding of the top ten holders of unrestricted shares".

Participation of Shareholders with more than 5% shareholding, top ten shareholders and top ten holders of unrestricted outstanding shares in re-lending business

☐ Applicable ☒ Not Applicable

Changes in top ten shareholders and top ten holders of unrestricted outstanding shares arising from re-lending/returning over the previous period

☐ Applicable ☒ Not Applicable

III. OTHER REMINDERS

Other important information about the operation of the Company during the Reporting Period that investors should be reminded of

√ Applicable ☐ Not Applicable

The continued increase in sales volume of the Company's core products, telitacicept and disitamab vedotin, drove steady growth in revenue from domestic commercial sales. Revenue from domestic commercial sales for the Reporting Period reached RMB810 million, representing an increase of 32.8% as compared with RMB610 million for the corresponding period last year and an increase of 15.6% as compared with RMB700 million for the second quarter. Cumulative revenue from commercial sales for the first three quarters amounted to RMB2,150 million, representing an increase of 26.1% as compared with RMB1,710 million for the corresponding period last year. Notwithstanding the price reductions under the medical insurance, the Company, through continuous cost control, maintained the gross profit margin of its domestic commercial sales at 83.6%, which was broadly in line with that of the corresponding period last year. In addition, with the economies of scale arising from the increase in sales volume, the selling expense ratio of domestic commercial sales (being the ratio of selling expenses to revenue from domestic commercial product sales) for the first three quarters decreased from 48.2% for the corresponding period last year to 40.5%, a decrease of 7.7 percentage points. Taking into account all the above factors, the Company recorded a profit in the first three quarters and the third quarter after excluding the effects of technology license revenue, the related costs, business development consultancy fees and the impact of changes in the fair value of warrants. In addition, given the significant increase in the receipts of technology licensing payments and commercial sales payments, the Company maintained sufficient cash and bills reserves. As at 30 September 2026, its cash and cash equivalents, bills receivable, receivables financing, bank wealth management products and other cash and bills amounted to approximately RMB3,898 million in aggregate.

IV. QUARTERLY FINANCIAL STATEMENTS

(i) Types of audit opinions

☐ Applicable ☒ Not Applicable

(ii) Financial statements

Consolidated Balance Sheet

30 September 2026

Prepared by: RemeGen Co., Ltd.*

Unit: RMB Currency: Renminbi Audit type: Unaudited

Item	30 September 2026	31 December 2025
Current assets:		
Cash and bank balances	972,135,684.91	1,197,548,786.32
Financial assets held for trading	4,545,628,810.69	1,215,510,584.77
Bills receivable	212,006,987.96	236,528,082.25
Accounts receivable	326,179,713.64	422,774,759.38
Receivables financing	227,930,555.83	58,785,548.20
Prepayments	144,904,235.23	91,744,403.64
Other receivables	55,575,111.90	84,025,528.45

Inventories	823,823,598.55	661,485,470.81
Other current assets	25,415,390.79	13,482,089.60
Total current assets	7,333,600,089.50	3,981,885,253.42
Non-current assets:		
Long-term equity investments	7,787,402.65	13,769,422.88
Investments in other equity instruments	15,363,666.77	115,174,185.71
Other non-current financial assets	10,084,227.81	10,084,227.81
Fixed assets	2,230,226,435.60	2,282,643,651.51
Construction in progress	675,916,008.41	646,823,147.81
Right-of-use assets	109,372,111.03	36,589,501.09
Intangible assets	146,651,017.30	152,484,577.29
Long-term deferred expenses	939,172.04	665,656.15
Other non-current assets	16,401,604.33	7,952,665.30
Total non-current assets	3,212,741,645.94	3,266,187,035.55
Total assets	10,546,341,735.44	7,248,072,288.97
Current liabilities:		
Short-term borrowings	158,529,720.12	1,221,760,613.73
Accounts payable	243,676,917.00	285,851,434.78
Contract liabilities	292,367,787.81	320,104,130.62
Payroll payable	241,506,185.36	217,483,490.55
Taxes payable	60,551,319.40	75,867,789.92
Other payables	391,847,220.41	399,672,514.63
Non-current liabilities due within one year	56,759,143.02	228,049,052.12
Other current liabilities	38,460,050.76	38,669,467.65
Total current liabilities	1,483,698,343.88	2,787,458,494.00
Non-current liabilities:		
Long-term borrowings	17,982,004.50	732,165,601.37
Lease liabilities	59,115,321.22	19,733,249.13
Deferred income	92,799,287.21	89,283,592.41
Deferred income tax liabilities	-	10,609,694.49
Total non-current liabilities	169,896,612.93	851,792,137.40
Total liabilities	1,653,594,956.81	3,639,250,631.40
Owners' equity (or shareholders' equity):		
Paid-in capital (or share capital)	564,477,483.00	563,710,243.00
Capital reserve	6,964,314,231.51	6,923,796,632.13
Less: Treasury shares	251,611,293.36	237,195,480.77
Other comprehensive income	-89,698,463.38	-34,773,858.14
Retained earnings	1,705,264,820.86	-3,606,715,878.65
Total equity attributable to owners (or shareholders) of the parent company	8,892,746,778.63	3,608,821,657.57
Total owners' equity (or shareholders' equity)	8,892,746,778.63	3,608,821,657.57
Total liabilities and owners' equity (or shareholders' equity)	10,546,341,735.44	7,248,072,288.97

The Company's legal
representative:
Wang Weidong

Person in charge of
accounting function:
Tong Shaojing

Person in charge of the
accounting department:
Wei Jianliang

Consolidated Statement of Income

January-September 2026

Prepared by: RemeGen Co., Ltd.*

Unit: RMB Currency: Renminbi Audit type: Unaudited

Item	First three quarters of 2026 (January-September)	First three quarters of 2025 (January-September)
I. Total operating revenue	6,763,781,382.06	1,719,833,029.78
Including: Operating revenue	6,763,781,382.06	1,719,833,029.78
II. Total operating costs	2,357,017,820.70	2,268,418,316.44
Including: Operating costs	409,196,943.70	270,593,449.58
Taxes and surcharges	14,638,189.91	12,367,642.39
Selling expenses	870,892,523.21	822,658,892.95
Administrative expenses	346,043,611.73	215,621,316.70
R&D expenses	695,272,999.40	890,583,907.36
Finance costs	20,973,552.75	56,593,107.46
Including: Interest expenses	19,448,715.71	57,040,326.33
Interest income	13,457,062.15	3,570,684.25
Add: Other income	16,061,062.80	19,145,615.59
Gain from investment (loss denoted by "-")	9,272,157.93	-4,686,557.89
Including: Gain from investments in associates and joint ventures	1,632,785.62	408,376.86
Gain from changes in fair value (loss denoted by "-")	853,859,566.03	293,722.97
Credit impairment loss (loss denoted by "-")	1,634,739.56	-3,632,557.18
Asset impairment loss (loss denoted by "-")	-166,527.75	-9,781.42
Income from disposal of assets (loss denoted by "-")	-1,234,169.82	205,690.01
III. Operating profit (loss denoted by "-")	5,286,190,390.11	-537,269,154.58
Add: Non-operating income	2,167,671.62	797,697.78
Less: Non-operating expenses	14,535,461.95	14,229,118.58
IV. Total profit (total loss denoted by "-")	5,273,822,599.78	-550,700,575.38
Less: Income tax expenses	591,485.25	-
V. Net profit (net loss denoted by "-")	5,273,231,114.53	-550,700,575.38

(i) By continuity of operations		
1. Net profit from continuing operations (net loss denoted by “-”)	5,273,231,114.53	-550,700,575.38
(ii) By attribution of ownership		
1. Net profit attributable to shareholders of the parent company (net loss denoted by “-”)	5,273,231,114.53	-550,700,575.38
VI. Other comprehensive income, net of tax	-16,175,020.26	49,592,840.32
(i) Other comprehensive income attributable to owners of the parent company, net of tax	-16,175,020.26	49,592,840.32
1. Other comprehensive income not to be reclassified to profit or loss	6,452,864.10	50,000,552.90
(1) Changes in fair value of other equity instruments investments	6,452,864.10	50,000,552.90

2. Other comprehensive income to be reclassified to profit or loss	-22,627,884.36	-407,712.58
(1) Translation differences of the financial statements in foreign currency	-22,627,884.36	-407,712.58
VII. Total comprehensive income	5,257,056,094.26	-501,107,735.06
(i) Total comprehensive income attributable to owners of the parent company	5,257,056,094.26	-501,107,735.06
VIII. Earnings per share:		
(i) Basic earnings per share (RMB/share)	9.41	-1.01
(ii) Diluted earnings per share (RMB/share)	9.37	-1.01

In case of a business combination under common control during the period, the net profit of the combined party which has been realised prior to the combination was RMB0, and the net profit of the combined party which has been realised in the previous period was RMB0.

The Company's legal representative:

Wang Weidong

Person in charge of accounting function:

Tong Shaojing

Person in charge of the accounting department:

Wei Jianliang

Consolidated Statement of Cash Flows

January-September 2026

Prepared by: RemeGen Co., Ltd.*

Unit: RMB Currency: Renminbi Audit type: Unaudited

Item	First three quarters of 2026 (January-September)	First three quarters of 2025 (January-September)
I. Cash flows from operating activities:		
Cash receipts from sales of goods and provision of services	6,488,217,436.41	2,229,797,482.86
Tax refund received	-	3,199.68
Cash received from other operating activities	68,082,068.04	26,135,188.33
Sub-total of cash inflows from operating activities	6,556,299,504.45	2,255,935,870.87
Cash paid for goods and services	362,421,357.45	104,074,192.63
Cash paid to and on behalf of employees	835,164,400.31	776,054,088.56
Cash paid for taxes and levies	205,446,867.52	106,451,519.86
Cash paid for other operating activities	1,069,572,476.73	1,052,298,635.88

Sub-total of cash outflows from operating activities	2,472,605,102.01	2,038,878,436.93
Net cash flows from operating activities	4,083,694,402.44	217,057,433.94
II. Cash flows from investment activities:		
Cash received from the disposal of investments	2,870,466,694.24	1,050,000,000.00
Cash received from investment income	13,750,034.58	1,606,295.09
Net cash received from the disposal of fixed assets, intangible assets and other long-term assets	3,149,369.00	1,610,219.63
Cash received from other investment activities	-	9,578,400.00
Sub-total of cash inflows from investment activities	2,887,366,097.82	1,062,794,914.72
Cash paid for acquisition of fixed assets, intangible assets and other long-term assets	107,778,232.17	175,212,674.86
Cash paid for investments	5,258,963,967.54	1,167,127,956.20
Sub-total of cash outflows from investment activities	5,366,742,199.71	1,342,340,631.06
Net cash flows from investing activities	-2,479,376,101.89	-279,545,716.34
III. Cash flows from financing activities:		
Cash received from capital contributions	59,831,245.42	783,623,475.65
Cash received from borrowings	363,972,782.32	1,333,647,815.42
Cash received from other financing activities	19,990,000.00	-
Sub-total of cash inflows from financing activities	443,794,027.74	2,117,271,291.07
Cash paid for repayment of debts	2,079,027,920.94	1,630,099,036.42
Cash paid for distribution of dividends or profits or settlement of interest	16,992,378.96	66,397,042.91
Cash paid for other financing activities	149,655,202.11	49,806,464.41
Sub-total of cash outflows from financing activities	2,245,675,502.01	1,746,302,543.74
Net cash flows from financing activities	-1,801,881,474.27	370,968,747.33
IV. Effects of changes in exchange rate on cash and cash equivalents	-11,373,038.07	-620,373.83
V. Net increase in cash and cash equivalents	-208,936,211.79	307,860,091.10
Add: Balance of cash and cash equivalents at the beginning of the period	1,154,598,527.93	759,530,043.42
VI. Balance of cash and cash equivalents at the end of the period	945,662,316.14	1,067,390,134.52

The Company's legal
representative:

Wang Weidong

Person in charge of
accounting function:

Tong Shaojing

Person in charge of the
accounting department:

Wei Jianliang

(iii) Adjustment of the financial statements for the beginning of 2026 when the Company implements the new accounting standards or interpretations for the first time

☐ Applicable ☒ Not Applicable

This is hereby notified.

Board of directors of RemeGen Co., Ltd.*

October 29, 2026